Healthcare
Live Price
Offline$0.011
+0.00% today
1Y Change
-99.91%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 244 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Trevena, Inc. (TRVN) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 99.9% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +847.6%, EPS growth of +58.4%, a dividend yield of 0.0%. What stands out right now is revenue +847.6%, EPS +58.4%, free cash flow +35.8% with operating margin -1129.2% and ROIC -103.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TRVN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRVN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRVN Max Drawdown
-99.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRVN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$31.0K
-99.0% YoY
FY Net Income
-$24.9M
+15.3% YoY
Free Cash Flow
-$23.7M
-10.5% YoY
Revenue Growth
+847.6%
EPS Growth
+58.4%
Gross Margin
46.6%
Net Margin
-1289.2%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 3M | -418K | 567K | 3M | 31K |
| Gross Profit | 1M | -3M | -387K | 3M | -77K |
| Operating Income | -35M | -56M | -52M | -29M | -27M |
| EBITDA | -35M | -52M | -51M | -29M | -26M |
| Net Income | -40M | -54M | -52M | -29M | -25M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33M | 38M | 67M | 109M | 32M |
| Total Assets | 41M | 49M | 80M | 128M | 47M |
| Total Liabilities | 48M | 33M | 15M | 24M | 17M |
| Shareholder Equity | -8M | 16M | 65M | 104M | 30M |
| Total Debt | 36M | 20M | 7M | 8M | 13M |
| Net Debt | 3M | -19M | -60M | -102M | -19M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
-10.6% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
24M
-10.5% YoY
Key ratios
Gross Margin
46.6%
Operating Margin
-1129.2%
Net Margin
-1289.2%
ROE
-1014.6%
Debt / Equity
-4.73x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.